Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a fresh partner in mRNA specialist BioNTech. BioNTech plans to invest up to 1 billion pounds sterling ($1.3 billion) over the next decade to beef up its R&D base in the U.K. The project will include the construction of two new research centers in the country, plus a U.K. headquarters for the German biopharma in London, which will also house an artificial intelligence “hub” led by BioNTech’s AI subsidiary InstaDeep. Source: Fierce Biotech 20/5/2025